Jill Quigley Sells 24,520 Shares of Terns Pharmaceuticals (NASDAQ:TERN) Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Director Jill Quigley sold 24,520 shares of the firm’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $18.00, for a total transaction of $441,360.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Terns Pharmaceuticals Trading Up 0.3%

Shares of TERN stock opened at $18.25 on Friday. The stock has a market cap of $1.60 billion, a P/E ratio of -17.55 and a beta of -0.02. Terns Pharmaceuticals, Inc. has a 1 year low of $1.87 and a 1 year high of $18.75. The stock has a 50 day simple moving average of $8.55 and a 200 day simple moving average of $5.88.

Terns Pharmaceuticals (NASDAQ:TERN) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.02. Analysts forecast that Terns Pharmaceuticals, Inc. will post -1.19 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently commented on TERN. Jefferies Financial Group boosted their price target on Terns Pharmaceuticals from $28.00 to $35.00 and gave the company a “buy” rating in a research note on Monday. Citigroup restated an “outperform” rating on shares of Terns Pharmaceuticals in a research report on Thursday, October 23rd. Truist Financial reiterated a “buy” rating and set a $28.00 price target (up previously from $20.00) on shares of Terns Pharmaceuticals in a research report on Tuesday. JMP Securities decreased their price objective on shares of Terns Pharmaceuticals from $20.00 to $15.00 and set a “market outperform” rating on the stock in a research note on Thursday, October 23rd. Finally, HC Wainwright upgraded Terns Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Tuesday. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $25.38.

Hedge Funds Weigh In On Terns Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in TERN. Profund Advisors LLC acquired a new stake in Terns Pharmaceuticals in the third quarter valued at approximately $96,000. Oppenheimer & Co. Inc. acquired a new position in shares of Terns Pharmaceuticals during the third quarter worth $94,000. AlphaQuest LLC lifted its stake in shares of Terns Pharmaceuticals by 9,088,200.0% in the 3rd quarter. AlphaQuest LLC now owns 90,883 shares of the company’s stock valued at $683,000 after acquiring an additional 90,882 shares during the last quarter. Engineers Gate Manager LP acquired a new stake in shares of Terns Pharmaceuticals during the 2nd quarter valued at $41,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Terns Pharmaceuticals by 11.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 506,777 shares of the company’s stock valued at $1,890,000 after acquiring an additional 52,796 shares in the last quarter. 98.26% of the stock is currently owned by institutional investors and hedge funds.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.